Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent

• US 6,673,773 B2
• Filed: 05/10/2002
• Issued: 01/06/2004
• Est. Priority Date: 05/10/2002
• Status: Expired

• Current Assignee: University Of Saskatchewan
• Original Assignee: University Of Saskatchewan
• Inventors: Prasad, Kailash
• Primary Examiner(s): Barts, Samuel
• Assistant Examiner(s): Henry, Michael C.
• Application Number:
  US10/141,860
• Publication Number:
  US 20030212007A1
• Time in Patent Office: 606 Days
• Field of Search: 514/25, 536/4.1, 536/1.1, 536/128, 530/500
• US Class Current: 514/25
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 51/1206 Administration of radioactive gases, aerosols or breath tests

Abstract

A method is described for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoportoein cholesterol. It involves administering to a patient a substantially pure complex derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.

Claims

1. A method for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoprotein cholesterol which comprises administering to a patient an effective amount of a complex having a purity of at least 95% derived from flaxseed and containing about 34 to 37% by weight secoisolariciresinol diglucoside (SDG), about 13 to 21% by weight cinnamic acid glucosides and about 9.6 to 11.0% by weight hydroxymethyl glutaric acid.

2. A method according to claim 1 wherein the cinnamic acid glucosides include coumaric acid glucoside and ferulic acid glucoside.